Testosterone Enanthate Patent Expiration
Testosterone Enanthate is Used for testosterone replacement therapy in individuals with low testosterone levels. It was first introduced by Endo Pharmaceuticals Inc
Testosterone Enanthate Patents
Given below is the list of patents protecting Testosterone Enanthate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Xyosted (autoinjector) | US10238662 | Needle assisted jet injection administration of testosterone compositions | Feb 19, 2035 | Antares Pharma Inc |
Xyosted (autoinjector) | US10279131 | Injection device with cammed RAM assembly | Jul 31, 2031 | Antares Pharma Inc |
Xyosted (autoinjector) | US10357609 | Needle assisted jet injection device having reduced trigger force | Aug 21, 2031 | Antares Pharma Inc |
Xyosted (autoinjector) | US10478560 | Prefilled syringe injector | Jan 24, 2026 | Antares Pharma Inc |
Xyosted (autoinjector) | US10646495 | Testosterone ester triglyceride formulations | Aug 30, 2038 | Antares Pharma Inc |
Xyosted (autoinjector) | US10821072 | Needle assisted jet injection administration of testosterone compositions | Jun 04, 2033 | Antares Pharma Inc |
Xyosted (autoinjector) | US10881798 | Needle assisted injection device having reduced trigger force | Feb 11, 2034 | Antares Pharma Inc |
Xyosted (autoinjector) | US10905827 | Injection device with cammed ram assembly | Aug 21, 2031 | Antares Pharma Inc |
Xyosted (autoinjector) | US10912782 | Needle assisted injection administration of testosterone compositions | Feb 19, 2035 | Antares Pharma Inc |
Xyosted (autoinjector) | US11160751 | Hematocrit modulation through needle assisted jet injection of testosterone | Oct 07, 2034 | Antares Pharma Inc |
Xyosted (autoinjector) | US11191908 | Syringe shock absorber for use in an injection device | Oct 18, 2035 | Antares Pharma Inc |
Xyosted (autoinjector) | US11446440 | Needle assisted injection device having reduced trigger force | Aug 21, 2031 | Antares Pharma Inc |
Xyosted (autoinjector) | US11446441 | Prefilled syringe injector | Jan 24, 2026 | Antares Pharma Inc |
Xyosted (autoinjector) | US11497753 | Hazardous agent injection system | Mar 19, 2030 | Antares Pharma Inc |
Xyosted (autoinjector) | US11771646 | Needle assisted jet injection administration of testosterone compositions | Apr 10, 2034 | Antares Pharma Inc |
Xyosted (autoinjector) | US11813435 | Needle assisted injection device having reduced trigger force | Feb 25, 2035 | Antares Pharma Inc |
Xyosted (autoinjector) | US11844804 | Administration of testosterone compositions | Jun 04, 2033 | Antares Pharma Inc |
Xyosted (autoinjector) | US8021335 | Prefilled syringe jet injector | Oct 04, 2026 | Antares Pharma Inc |
Xyosted (autoinjector) | US8562564 | Prefilled syringe jet injector | Jan 24, 2026 | Antares Pharma Inc |
Xyosted (autoinjector) | US9180259 | Prefilled syringe jet injector | Jan 24, 2026 | Antares Pharma Inc |
Xyosted (autoinjector) | US9533102 | Prefilled syringe jet injector | Jan 24, 2026 | Antares Pharma Inc |
Xyosted (autoinjector) | US9629959 | Prefilled syringe jet injector | Jan 24, 2026 | Antares Pharma Inc |
Xyosted (autoinjector) | US9744302 | Needle assisted jet injection device having reduced trigger force | Nov 19, 2035 | Antares Pharma Inc |
Xyosted (autoinjector) | US9950125 | Needle assisted jet injection administration of testosterone compositions | Sep 04, 2036 | Antares Pharma Inc |
Xyosted (autoinjector) | USRE44846 | Needle assisted jet injector |
Aug 10, 2019
(Expired) | Antares Pharma Inc |
Xyosted (autoinjector) | USRE44847 | Needle assisted jet injector |
Aug 10, 2019
(Expired) | Antares Pharma Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Testosterone Enanthate's patents.
Latest Legal Activities on Testosterone Enanthate's Patents
Given below is the list recent legal activities going on the following patents of Testosterone Enanthate.
Event | Date | Patent/Publication |
---|---|---|
![]() | ||
Payment of Maintenance Fee, 4th Year, Large Entity | 01 Jul, 2024 | US10881798 |
Payment of Maintenance Fee, 4th Year, Large Entity | 01 May, 2024 | US10821072 |
Email Notification | 20 Dec, 2023 | US11844804 |
Recordation of Patent Grant Mailed | 19 Dec, 2023 | US11844804 |
Patent eGrant Notification | 19 Dec, 2023 | US11844804 |
Recordation of Patent eGrant | 19 Dec, 2023 | US11844804 |
Patent Issue Date Used in PTA Calculation | 19 Dec, 2023 | US11844804 |
Mail Patent eGrant Notification | 19 Dec, 2023 | US11844804 |
Email Notification | 30 Nov, 2023 | US11844804 |
Issue Notification Mailed | 29 Nov, 2023 | US11844804 |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳
Testosterone Enanthate Generics
Several generic applications have been filed for Testosterone Enanthate. The first generic version for Testosterone Enanthate was by Watson Laboratories Inc and was approved on Approved Prior to Jan 1, 1982. And the latest generic version is by Eugia Pharma Specialities Ltd and was approved on Feb 28, 2024.
Given below is the list of companies who have filed for Testosterone Enanthate generic.
1. RISING
Rising Pharma Holding Inc has filed for 1 generic for Testosterone Enanthate. Given below are the details of the strengths of this generic introduced by Rising.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
200MG/ML | injectable | Discontinued | INJECTION | N/A | Oct 5, 2009 |
2. WATSON LABS
Watson Laboratories Inc has filed for 2 different strengths of generic version for Testosterone Enanthate. Given below are the details of the strengths of this generic introduced by Watson Labs.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
100MG/ML | injectable | Discontinued | INJECTION | N/A | Approved Prior to Jan 1, 1982 |
200MG/ML | injectable | Discontinued | INJECTION | N/A | Approved Prior to Jan 1, 1982 |
3. NEXUS
Nexus Pharmaceuticals Llc has filed for 1 generic for Testosterone Enanthate. Given below are the details of the strengths of this generic introduced by Nexus.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
200MG/ML | injectable | Prescription | INJECTION | AO | Jun 14, 2006 |
4. HIKMA FARMACEUTICA
Hikma Farmaceutica Portugal Sa has filed for 1 generic for Testosterone Enanthate. Given below are the details of the strengths of this generic introduced by Hikma Farmaceutica.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
200MG/ML | injectable | Prescription | INJECTION | AO | Sep 18, 2012 |
5. WATSON PHARMS INC
Watson Pharmaceuticals Inc has filed for 1 generic for Testosterone Enanthate. Given below are the details of the strengths of this generic introduced by Watson Pharms Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
200MG/ML
(reference standard) | injectable | Prescription | INJECTION | AO | Approved Prior to Jan 1, 1982 |
6. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Testosterone Enanthate. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
200MG/ML | injectable | Prescription | INJECTION | AO | Feb 28, 2024 |